With the discovery of isocitrate dehydrogenase (IDH1 and IDH2) mutations in cancer and the associated accumulation of an unique de novo product, 2-hydroxyglutarate (2HG), the phrase ‘oncometabolites’ was coined (Dang et al., 2009). The gene discussed is IDH2; the disease is cancer.